Learn More
Immunohistochemical characterization of three monoclonal antibodies (MAbs), designated 323/A3, SF-25 and K928, on a panel of 330 head and neck and lung tumours indicated their potential for(More)
So far, mAb E48 is the most promising antibody described for specific targeting of head and neck squamous cell carcinoma (HNSCC) in patients. On the basis of its more homogeneous reactivity pattern(More)